Join Humacyte for a virtual investor event featuring KOL Mohamad A. Hussain, MD, PhD, RPVI, FAHA, FRCSC, FACS (Brigham & Women’s Hospital, Center for Surgery and Public Health, Harvard Medical School), who will join company management to discuss the unmet need and current treatment landscape for hemodialysis patients with End-Stage Renal Disease (ESRD).

The event will provide an overview of the Company’s investigational Acellular Tissue Engineered Vessel (ATEV), and review positive interim clinical data from its Phase 3 V012 study. The current standard of care for providing AAV access involves connecting the patient’s artery with a vein, known as an arteriovenous fistula or AV fistula (AVF). In a prespecified interim analysis conducted in the first 80 patients enrolled in the study, Humacyte’s ATEV met the superiority primary endpoint after one year of follow up, with ATEV observed to have an average of 91 more catheter-free days compared to AVF. Data from the V012 trial were presented at the Society for Vascular Surgery’s (SVS’s) Vascular Annual Meeting (VAM) and featured at the Women’s Health seminar June 11^th in Boston.

A live question and answer session will follow the formal presentations.